Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
Conditions
Interventions
DPI-386 Nasal Gel
Placebo
Locations
1
United States
Santa Monica Clinical Trials
Santa Monica, California, United States
Start Date
August 23, 2022
Primary Completion Date
November 29, 2022
Completion Date
November 29, 2022
Last Updated
March 21, 2023
NCT03772340
NCT06056622
NCT04420949
NCT05628220
NCT04331561
NCT03986905
Lead Sponsor
Repurposed Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions